Phase 1 NASH Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
Evaluating the Pharmacokinetics and Safety of Miricorilant
Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 1
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
NASH
BAR Pharmaceuticals s.r.l.52 enrolled1 locationNCT06705998
Recruiting
Phase 1
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NASH - Nonalcoholic SteatohepatitisNAFLD - Non-Alcoholic Fatty Liver Disease
Tasly Biopharmaceuticals Co., Ltd.32 enrolled5 locationsNCT07128797
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
Nonalcoholic Steatohepatitis (NASH)
Changchun Intellicrown Pharmaceutical Co. LTD138 enrolled1 locationNCT06216041
Completed
Phase 1
A first in human study to Evaluate the Safety and Tolerability of OLX75016 for treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis.
(NAFLD) to steatohepatitis (NASH)Cirrhosis
OliX AU Pty Ltd58 enrolled1 locationACTRN12624000023550
Completed
Phase 1
A Phase 1 Open-Label, Parallel-Group, Two-Treatment, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9674 and GS-0976 in Subjects with Normal Renal Function and Severe Renal Impairment
Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences Inc20 enrolled4 locationsACTRN12619000655145
Completed
Phase 1
A Single Oral Dose Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) Patients and Healthy Volunteers
Nonalcoholic Steatohepatitis (NASH)
INC Research32 enrolled1 locationACTRN12615001355561